Harry Moseley
University of Dundee
124 Papers
911 Citations
Harry Moseley is an academic researcher from University of Dundee. The author has contributed to research in topics: Medicine & Photodynamic therapy. The author has an hindex of 33, co-authored 124 publications. Previous affiliations of Harry Moseley include Ninewells Hospital.
Chat about Author
Papers
Laser and Non-laser Light Sources for Photodynamic Therapy
L. Brancaleon,Harry Moseley +1 more
TL;DR: The important characteristics of light sources for PDT, including dye lasers pumped by argon or metal vapour lasers and frequency-doubled Nd:YAG lasers are considered, and the relative merits of laser and non-laser sources are critically examined.
504
Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group
Colin A. Morton,S B Brown,S Collins,Sally H. Ibbotson,H Jenkinson,H. Kurwa,K Langmack,K McKenna,Harry Moseley,Anthony D. Pearse,Mark R. Stringer,D K Taylor,G Wong,Lesley E. Rhodes +13 more
TL;DR: Current evidence indicates topical PDT to be effective in actinic keratoses on the face and scalp, Bowen's disease and superficial basal cell carcinomas, and several non‐coherent and coherent light sources are effective in PDT.
487
Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease
TL;DR: PDT using a non‐laser light source and topical 5‐ALA appears to be at least as effective as cryotherapy in the treatment of Bowen's disease with fewer adverse effects.
287
ALA and Photofrin® Fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial
TL;DR: ALA and Photofrin® fluorescence-guided resection and repetitive PDT offered a worthwhile survival advantage without added risk to patients with GBM.
281
Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources
TL;DR: Topical 5‐aminolaevulinic acid (ALA) photodynamic therapy (PDT) is increasingly used for superficial non‐melanoma skin cancers and their precursors.
168